Showing results (21-30 of 327) with videos related to
Sort By:
Pageof 33
The Journal of Clinical Investigation|June 1, 1983
Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidationM B Penno, E S VesellClinical Pharmacology and Therapeutics|October 1, 1975
Temporal variations in acetaminophen and phenacetin half-life in manC A Shively, E S VesellToxicology|April 27, 2000
Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitusE S Vesell, K H BeyerClinical Pharmacology and Therapeutics|June 1, 1975
Unaltered metabolism of antipyrine and tolbutamide in fasting manM M Reidenberg, E S VesellJournal of Clinical Pharmacology|November 1, 1979
Interaction between sulindac and warfarin: different results in normal subjects and in an unusual patient with a potassium-losing renal tubular defectJ P Loftin, E S VesellClinical Pharmacokinetics|September 1, 1983
Assessment of methods to identify sources of interindividual pharmacokinetic variationsE S Vesell, M B PennoProceedings of the National Academy of Sciences of the United States of America|January 1, 1980
Enhanced drug-metabolizing capacity within liver adjacent to human and rat liver tumorsL G Sultatos, E S VesellDrug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1987
In vivo and in vitro biotransformation of theobromine by phenobarbital- and 3-methylcholanthrene-inducible cytochrome P-450 monooxygenases in rat liver. Role of thiol compoundsC A Shively, E S VesellScience (New York, N.Y.)|April 26, 1974
Liquid chromatographic assay of warfarin: similarity of warfarin half-lives in human subjectsE S Vesell, C A ShivelyPharmacology|January 1, 1975
Anomalous results of studies on drug interaction in man. II. Halofenate (mk-185) and antipyrine, bishydroxycoumarin, and warfarinE S Vesell, G T PassanantiPageof 33